Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Khedhaier, Achraf ^a   Hassen, Elham ^a   Bouaouina, Noureddine ^a,b   Gabbouj, Sallouha ^a   Ahmed, Slim Ben ^b   Chouchane, Lotfi ^a,c  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FARHAT HACHED HOSPITAL   (Tunisia)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; EPOXIDE HYDROLASE; MICROSOMAL EPOXIDE HYDROLASE; XENOBIOTIC AGENT; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; NAT2 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MUTANT; ONSET AGE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREDICTION; PROGNOSIS; RESTRICTION MAPPING; WILD TYPE; BREAST TUMOR; COMPARATIVE STUDY; DRUG DETOXIFICATION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; DISEASE-FREE SURVIVAL; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 43749116210     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-109     Document Type: Article

References (41)

1. Parkin DM International variation Oncogene 2004, 23:6329-40. 10.1038/ sj.onc.1207726 15322508
2. Stewart SL King JB Thompson TD Friedman C Wingo PA Cancer mortality surveillance-United States, 1990-2000 MMWR Surveill Summ 2004, 53:1-108. 15179359
3. Jemal A Thomas A Murray T Thun M Cancer statistics CA Cancer J Clin 2002, 52:23-47. 11814064
4. Bray F Sankila R Ferlay J Parkin DM Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 2002, 38:99-166. 10.1016/ S0959-8049(01)00350-1 11750846
5. Ben Ahmed S Aloulou S Bibi M Landolsi A Nouira M Ben Fatma L Kallel L Gharbi O Korbi S Khaïri H Kraïem C Breast cancer detection in Tunisian women: An analysis of a hospital trial involving 729 patients Santé Publique 2002, 14:231-41.
6. Dumitrescu RG Cotaria I Undrestanding breast cancer risk - Where do we stand in 2005 J Cell Mol Med 2005, 9:208-21. 10.1111/ j.1582-4934.2005.tb00350.x 15784178
7. Bennett IL Gattas M Teh BT Genetic basis of breast cancer and its clinical implications Aust N Z J Surg 1999, 69:95-105. 10.1046/ j.1440-1622.1999.01515.x 10030809
8. Rothman N Wacholder S Caporaso NE Garcia-Closas M Buetow K Fraumeni JF The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens Biochim Biophys Acta 2001, 1471:C1-10. 11342183
9. Han W Kang D Park IA Kim SW Bae JY Chung KW Noh DY Associations between breast cancer susceptibility gene polymorphisms and clinicalpathological features Clin Cancer Res 2004, 10:124-30. 10.1158/1078-0432.CCR-0834-3 14734460
10. Chacko P Joseph T Mathew BS Rajan B Pillai MR Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome Mut Res 2005, 581:153-63. 15725614
11. Hurst R Bao Y Jemth P Mannervik B Williamson G Phospholipid hydroperoxide glutathione peroxidase activity of human glutathione transferases Biochem J 1998, 332:97-100. 1219456 9576856
12. Biéche I Girault I Urbain E Tozlu S Lidereau R Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma Breast Cancer Res 2004, 6:R252-63. 400681 15084249 10.1186/bcr784
13. Khedhaier A Remadi S Corbex M Ben Ahmed S Bouaouina N Mestiri S Azaiez R Helal AN Chouchane L Glutathione-S-transferases (GSTT1 and GSTM1) gene deletions in tunisians: Susceptibility and prognostic implications in breast carcinoma Br J Cancer 2003, 89:1502-7. 10.1038/sj.bjc.6601292 14562023
14. Olerup O Zetterquist H HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in two hours: An alternative to serological DR typing in clinical practice including donor recipient matching in cadaveric transplantation Tissue Antigens 1992, 39:225-35. 1357775
15. Salama SA Sierra-Torres CH Oh HY Hamada FA Au WW A multiplex-PCR/RFLP procedure for simultaneous CYP2E1, mEH and GSTM1 genotyping Cancer Lett 1999, 143:51-6. 10.1016/S0304-3835(99)00192-5 10465337
16. De Morais SM Wilkinson GR Blaisdell J Nakamura K Meyer UA Goldstein JA The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 1994, 269:15419-22. 8195181
17. Lemos MC Cabrita FJ Silva HA Vivan M Placido F Regateiro FJ Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias Carcinogenesis 1999, 20:1225-9. 10.1093/carcin/ 20.7.1225 10383893
18. De Jong MM Nolte IM Te Meerman GJ Van der Graaf WT Oosterwijk JC Kleibeuker JH Schaapveld M de Vries EG Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J Med Genet 2002, 39:225-42. 1735082 11950848 10.1136/jmg.39.4.225
19. Ladona MG Abildua RE Ladero JM Roman JM Plaza MA Aqundez JA Muñoz JJ Benítez J CYP2D6 genotypes in spanish women with breast cancer Cancer lett 1996, 99:23-8. 10.1016/0304-3835(95)04033-1 8564925
20. Lemos MC Carrilho F Rodrigues F Coutinho E Gomes L Carvalheiro M Regateiro FJ Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer Clin Endocrinol 2007, 67:180-3. 10.1111/ j.1365-2265.2007.02858.x 17547692
21. Rostami-Hodjegan A Lennard MS Woods HF Tucker GT Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease Pharmacogenetics 1998, 8:227-38. 10.1097/ 00008571-199806000-00005 9682268
22. Tucker AN Tkaczuk KA Lewis LM Tomic D Lim CK Flaws JA Polymorphisms in cytochrome P 450 3A5(CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients Cancer lett 2005, 217:61-72. 10.1016/ j.canlet.2004.08.027 15596297
23. Hanioka N Kimura S Meyer UA Gonzalez FJ The human CYP2D6 locus associated with common genetic defect in drug oxidation: A G1934A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site Am J Hum Genet 1990, 47:994-1001. 1683916 1978565
24. Wegman P Vainikka L Stal O Nordenskjold B Skoog L Rutqvist LE Wingren S Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast cancer Res 2005, 7:R284-90. 1143572 15987423 10.1186/bcr993
25. Agundez JA Cytochrome P450 gene polymorphism and cancer Curr Drug Metab 2004, 5:211-24. 10.2174/1389200043335621 15180491
26. Scordo MG Caputi AP D'Arrigo C Fava G Spina E Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population Pharmacol Res 2004, 50:195-200. 10.1016/j.phrs.2004.01.004 15177309
27. Hamdy SI Hiratsuka M Narahara K El-Enany M Moursi N Ahmed MS Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population Br J Clin Pharmacol 2002, 53:596-603. 1874334 12047484 10.1046/j.1365-2125.2002.01604.x
28. Ruas JL Lechner MC Allele frequency of CYP2C19 in a Portuguese population Pharmacogenetics 1997, 7:333-5. 10.1097/ 00008571-199708000-00009 9295062
29. Ferreira PM Medeiros R Vasconcelos A Costa S Pinto D Morais A Association between CYP2E1 polymorphisms and susceptibility to prostate cancer Eur J Cancer Prev 2003, 12:205-11. 10.1097/ 00008469-200306000-00007 12771559
30. Hassett C Aicher L Sidhu JS Omiecinski CJ Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amine acid variants Hum Mol Genet 1994, 3:421-8. 10.1093/hmg/3.3.421 7516776
31. London SJ Smart J Daly AK Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americains and Caucasians in Los Angeles country Lung Cancer 2000, 28:147-55. 10.1016/S0169-5002(99)00130-0 10717332
32. Jourenkova-Mironova N Mitrunen K Bouchardy C Dayer P Benhamou S Hirvonen A High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx and larynx cancers Cancer Res 2000, 60:534-6. 10676631
33. Baxter SW Choong DY Campbell IG Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer Cancer Lett 2002, 177:75-81. 10.1016/S0304-3835(01)00782-0 11809533
34. Dupret JM Rodrigues-Lima F Structure and regulation of the Drug-Metabolizing Enzymes Arylamine N-Acetyltransferases Curr Med Chem 2005, 12:311-8. 15723621
35. Alberg AJ Daudt A Huang HY Hoffman SC Comstock GW Helzlsouer KJ Strickland PT Bell DA N-acetyltransferase-2 (NAT2) genotypes, cigarette smoking and risk of breast cancer Cancer Detect Prev 2004, 28:187-93. 10.1016/j.cdp.2004.04.001 15225898
36. Kuo HW Chou SY Hu TW Wu FY Chen DJ Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) and genetic polymorphisms in breast cancer patients Mutat Res 2007, 631:62-8. 17512776
37. Chang-Claude J Kropp S Jager B Bartsch H Risch A Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk Cancer Epidemiol Biomarkers Prev 2002, 11:698-704. 12163321
38. Costa S Medeiros R Vasconcelos A Pinto D Lopes C A slow acetylator genotype associated with an increased risk of advanced cervical cancer J Cancer Res Clin Oncol 2002, 128:678-82. 10.1007/s00432-002-0391-9 12474054
39. Costa S Pinto D Morais A Vasconcelos A Oliveira J Lopes C Medeiros R Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population Prostate 2005, 64:246-52. 10.1002/ pros.20241 15717312
40. Narod SA Modifiers of risk of hereditary breast and ovarian cancer Nat Rev Cancer 2002, 2:113-23. 10.1038/nrc726 12635174
41. Fritz P Murdter TE Eichelbaum M Siegle I Weissert M Zanger UM Microsomal epoxide hydrolase expression as a predictor of tamoxifen response in primary breast cancer: A retrospective exploratory study with long-term follow-up J Clin Oncol 2001, 19:3-9. 11134189